Last reviewed · How we verify

Umeclidinium/Vilanterol 62.5/25 mcgs

National Institute of Respiratory Diseases, Mexico · FDA-approved active Small molecule

Umeclidinium/Vilanterol 62.5/25 mcgs is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Small molecule drug developed by National Institute of Respiratory Diseases, Mexico. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance treatment. Also known as: Anoro.

Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to reduce airway smooth muscle contraction, while vilanterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing dual bronchodilation for sustained airway opening.

Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to reduce airway smooth muscle contraction, while vilanterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing dual bronchodilation for sustained airway opening. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

At a glance

Generic nameUmeclidinium/Vilanterol 62.5/25 mcgs
Also known asAnoro
SponsorNational Institute of Respiratory Diseases, Mexico
Drug classLong-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)
TargetM3 muscarinic receptor; beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Mechanism of action

Umeclidinium competitively antagonizes M3 muscarinic receptors on airway smooth muscle, reducing acetylcholine-induced bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and promoting smooth muscle relaxation. The combination provides complementary mechanisms for sustained bronchodilation over 24 hours.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Umeclidinium/Vilanterol 62.5/25 mcgs

What is Umeclidinium/Vilanterol 62.5/25 mcgs?

Umeclidinium/Vilanterol 62.5/25 mcgs is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drug developed by National Institute of Respiratory Diseases, Mexico, indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

How does Umeclidinium/Vilanterol 62.5/25 mcgs work?

Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to reduce airway smooth muscle contraction, while vilanterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing dual bronchodilation for sustained airway opening.

What is Umeclidinium/Vilanterol 62.5/25 mcgs used for?

Umeclidinium/Vilanterol 62.5/25 mcgs is indicated for Chronic obstructive pulmonary disease (COPD) maintenance treatment.

Who makes Umeclidinium/Vilanterol 62.5/25 mcgs?

Umeclidinium/Vilanterol 62.5/25 mcgs is developed and marketed by National Institute of Respiratory Diseases, Mexico (see full National Institute of Respiratory Diseases, Mexico pipeline at /company/national-institute-of-respiratory-diseases-mexico).

Is Umeclidinium/Vilanterol 62.5/25 mcgs also known as anything else?

Umeclidinium/Vilanterol 62.5/25 mcgs is also known as Anoro.

What drug class is Umeclidinium/Vilanterol 62.5/25 mcgs in?

Umeclidinium/Vilanterol 62.5/25 mcgs belongs to the Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class. See all Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) drugs at /class/long-acting-muscarinic-antagonist-long-acting-beta-2-agonist-combination-lama-laba.

What development phase is Umeclidinium/Vilanterol 62.5/25 mcgs in?

Umeclidinium/Vilanterol 62.5/25 mcgs is FDA-approved (marketed).

What are the side effects of Umeclidinium/Vilanterol 62.5/25 mcgs?

Common side effects of Umeclidinium/Vilanterol 62.5/25 mcgs include Tremor, Headache, Palpitations, Dry mouth, Nasopharyngitis.

What does Umeclidinium/Vilanterol 62.5/25 mcgs target?

Umeclidinium/Vilanterol 62.5/25 mcgs targets M3 muscarinic receptor; beta-2 adrenergic receptor and is a Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA).

Related